See more : Eastnine AB (publ) (EAST.ST) Income Statement Analysis – Financial Results
Complete financial analysis of SWK Holdings Corporation (SWKH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of SWK Holdings Corporation, a leading company in the Asset Management industry within the Financial Services sector.
You may be interested
- Sievi Capital Plc (SIEVI.HE) Income Statement Analysis – Financial Results
- Savosolar Oyj (SAVOH.HE) Income Statement Analysis – Financial Results
- K.C. Metalsheet Public Company Limited (KCM.BK) Income Statement Analysis – Financial Results
- Peabody Energy Corporation (BTU) Income Statement Analysis – Financial Results
- Genius Sports Limited (GENI) Income Statement Analysis – Financial Results
SWK Holdings Corporation (SWKH)
About SWK Holdings Corporation
SWK Holdings Corporation, a specialty finance company that focuses on the healthcare sector. It operates in two segments, Finance Receivables and Pharmaceutical Development. The company provides customized financing solutions to a range of life science companies, including companies in the biotechnology, medical device, medical diagnostics and related tools, animal health, and pharmaceutical industries, as well as institutions and inventors. It also offers non-discretionary investment advisory services to institutional clients in separately managed accounts to invest in life science finance. In addition, the company engages in the pharmaceutical development, formulation and manufacturing, and licensing business through the Peptelligence platform. Further, it intends to out-license its internal product pipeline to create novel formulations using its proprietary technology to develop treatments for patients and caregivers. The company was formerly known as Kana Software, Inc. and changed its name to SWK Holdings Corporation in December 2009. SWK Holdings Corporation was founded in 1996 and is headquartered in Dallas, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 37.76M | 41.48M | 56.16M | 36.71M | 30.75M | 25.99M | 37.49M | 22.38M | 23.46M | 17.40M | 6.45M | 637.00K | 0.00 | 0.00 | 45.26M | 65.22M | 60.79M | 54.03M | 43.13M | 48.90M | 61.01M | 79.09M | 86.87M | 119.25M | 14.10M | 2.00M |
| Cost of Revenue | 3.44M | 6.95M | 7.35M | 4.27M | 1.18M | 0.00 | 0.00 | 0.00 | 10.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 16.54M | 20.69M | 17.24M | 12.90M | 11.74M | 11.94M | 12.83M | 32.65M | 50.61M | 50.05M | 5.40M | 400.00K |
| Gross Profit | 34.32M | 34.53M | 48.81M | 32.44M | 29.57M | 25.99M | 37.49M | 22.38M | 23.45M | 17.40M | 6.45M | 637.00K | 0.00 | 0.00 | 28.72M | 44.53M | 43.55M | 41.13M | 31.39M | 36.96M | 48.18M | 46.44M | 36.26M | 69.20M | 8.70M | 1.60M |
| Gross Profit Ratio | 90.90% | 83.24% | 86.92% | 88.37% | 96.18% | 100.00% | 100.00% | 100.00% | 99.96% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 63.45% | 68.28% | 71.64% | 76.13% | 72.78% | 75.59% | 78.97% | 58.72% | 41.74% | 58.03% | 61.70% | 80.00% |
| Research & Development | 0.00 | 6.95M | 7.35M | 4.27M | 1.18M | 0.24 | 0.88 | 0.64 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 12.85M | 13.82M | 12.65M | 10.77M | 13.23M | 19.50M | 21.44M | 25.93M | 35.56M | 42.72M | 12.90M | 2.30M |
| General & Administrative | 11.23M | 12.96M | 13.62M | 10.55M | 7.43M | 4.88M | 4.10M | 2.83M | 3.38M | 3.28M | 1.75M | 2.24M | 1.55M | 1.76M | 8.70M | 10.57M | 0.00 | 0.00 | 11.38M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 9.19M | 22.30M | 0.00 | 0.00 | 17.67M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 11.23M | 12.96M | 13.62M | 10.55M | 7.43M | 4.88M | 4.10M | 2.83M | 3.38M | 3.28M | 1.75M | 2.24M | 1.55M | 1.76M | 17.89M | 32.87M | 37.16M | 29.80M | 29.09M | 33.24M | 38.26M | 50.48M | 90.85M | 107.13M | 26.20M | 4.50M |
| Other Expenses | 8.44M | -862.00K | 4.06M | 12.09M | 7.16M | 6.18M | -5.22M | 1.66M | 10.85M | -129.00K | -60.00K | 0.00 | 0.00 | 0.00 | 5.06M | 500.00K | 288.00K | 133.00K | 6.46M | 2.41M | 7.32M | 76.42M | 746.99M | 896.75M | 82.00M | 1.50M |
| Operating Expenses | 19.67M | 19.05M | 17.68M | 22.64M | 14.59M | 11.06M | 4.10M | 4.49M | 14.23M | 3.28M | 1.75M | 2.24M | 1.55M | 1.76M | 35.79M | 47.19M | 50.10M | 40.70M | 48.78M | 55.15M | 67.02M | 152.83M | 873.39M | 1.05B | 121.10M | 8.30M |
| Cost & Expenses | 19.35M | 26.01M | 25.03M | 26.91M | 15.77M | 11.06M | 4.10M | 4.49M | 14.23M | 3.28M | 1.75M | 2.24M | 1.55M | 1.76M | 52.33M | 67.88M | 67.34M | 53.60M | 60.52M | 67.08M | 79.85M | 185.48M | 924.00M | 1.10B | 126.50M | 8.70M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 15.84M | 17.53M | 10.00K | 49.00K | 158.00K | 254.00K | 275.00K | 7.00K | 27.00K | 87.00K | 172.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.85M | 340.00K | 374.00K | 455.00K | 338.00K | 160.00K | 0.00 | 0.00 | 381.00K | 589.00K | 68.00K | 158.00K | 254.00K | 275.00K | 978.00K | 369.00K | 858.00K | 207.00K | 88.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.91M | 26.12M | 22.92M | 28.08M | 14.10M | 11.61M | 5.22M | 3.90M | 10.00K | 3.00K | 2.00K | 5.00K | 2.00K | 275.00K | 1.69M | 1.78M | 1.30M | 1.59M | 2.46M | 6.82M | 15.41M | 30.55M | 153.61M | 896.75M | 82.00M | 1.50M |
| EBITDA | 19.04M | 12.43M | 37.45M | 21.90M | 19.93M | 13.89M | 42.77M | 17.89M | -326.00K | 7.95M | 4.44M | -1.60M | -1.55M | -177.00K | 1.69M | -1.51M | -5.25M | 1.59M | -17.86M | -12.59M | -9.30M | -75.84M | -683.52M | -2.17B | -30.60M | -11.00M |
| EBITDA Ratio | 50.42% | 44.13% | 62.66% | 59.65% | 64.83% | 53.46% | 114.09% | 79.95% | 39.40% | 81.25% | 71.88% | -250.86% | 0.00% | 0.00% | -11.88% | -1.31% | -7.75% | 8.55% | -19.07% | -14.37% | -2.32% | -33.94% | 25.20% | 1,687.94% | -170.92% | -270.00% |
| Operating Income | 14.65M | 15.48M | 31.13M | 9.81M | 14.98M | 14.93M | 33.39M | 17.89M | 2.60M | 14.13M | 4.70M | -1.60M | -1.55M | -1.76M | -8.42M | -3.24M | -7.12M | -271.00K | -17.86M | -21.58M | -20.55M | -101.31M | -939.62M | -977.40M | -112.40M | -6.70M |
| Operating Income Ratio | 38.80% | 37.31% | 55.43% | 26.71% | 48.71% | 57.44% | 89.06% | 79.95% | 11.07% | 81.18% | 72.90% | -251.65% | 0.00% | 0.00% | -18.60% | -4.97% | -11.70% | -0.50% | -41.41% | -44.13% | -33.68% | -128.09% | -1,081.64% | -819.64% | -797.16% | -335.00% |
| Total Other Income/Expenses | -37.00K | -477.00K | 1.88M | -22.05M | -3.93M | -673.00K | -9.38M | -7.49M | -3.69M | -824.00K | -209.00K | 158.00K | 453.00K | 1.03M | 43.31M | -411.00K | -739.00K | -1.94M | 88.00K | 128.00K | -314.00K | 913.00K | -705.42M | -2.09B | -6.30M | 6.40M |
| Income Before Tax | 14.61M | 9.49M | 33.01M | 3.67M | 16.84M | 6.24M | 24.00M | 10.40M | -1.09M | 13.30M | 4.49M | -1.45M | -1.09M | -727.00K | 34.90M | -3.65M | -7.85M | -2.21M | -17.77M | -21.45M | -20.86M | -150.31M | -1.65B | -3.07B | -118.70M | -6.50M |
| Income Before Tax Ratio | 38.70% | 22.88% | 58.79% | 9.98% | 54.78% | 24.00% | 64.03% | 46.48% | -4.65% | 76.44% | 69.66% | -226.84% | 0.00% | 0.00% | 77.10% | -5.60% | -12.92% | -4.08% | -41.20% | -43.87% | -34.19% | -190.04% | -1,893.68% | -2,575.22% | -841.84% | -325.00% |
| Income Tax Expense | -1.27M | -4.00M | 7.08M | -1.54M | -6.99M | 42.00K | 15.75M | -21.64M | 3.27M | -10.30M | -9.84M | -24.00K | -26.00K | -20.00K | 3.00K | 5.00K | 167.00K | 219.00K | 196.00K | 314.00K | 318.00K | -10.28M | 105.76M | 2.09B | 6.40M | -400.00K |
| Net Income | 15.89M | 13.49M | 25.93M | 5.20M | 23.83M | 6.20M | 3.05M | 28.89M | -7.37M | 20.77M | 12.86M | -1.42M | -1.07M | -707.00K | 34.89M | -3.66M | -8.02M | -2.43M | -17.97M | -21.77M | -20.97M | -96.11M | -942.90M | -3.07B | -118.80M | -6.30M |
| Net Income Ratio | 42.07% | 32.52% | 46.17% | 14.17% | 77.50% | 23.84% | 8.13% | 129.08% | -31.42% | 119.34% | 199.50% | -223.08% | 0.00% | 0.00% | 77.10% | -5.60% | -13.19% | -4.49% | -41.66% | -44.52% | -34.37% | -121.52% | -1,085.41% | -2,575.22% | -842.55% | -315.00% |
| EPS | 1.26 | 1.05 | 2.03 | 0.40 | 1.85 | 0.47 | 0.23 | 2.22 | -0.57 | 3.20 | 3.10 | -0.34 | -0.26 | -0.17 | 8.50 | -0.89 | -2.16 | -0.70 | -5.83 | -7.52 | -8.72 | -42.90 | -686.09 | -3.96K | -773.72 | -100.67 |
| EPS Diluted | 1.25 | 1.05 | 2.02 | 0.40 | 1.85 | 0.47 | 0.23 | 2.22 | -0.57 | 3.20 | 3.10 | -0.34 | -0.26 | -0.17 | 8.50 | -0.89 | -2.16 | -0.70 | -5.83 | -7.52 | -8.72 | -42.90 | -686.09 | -3.96K | -773.72 | -100.67 |
| Weighted Avg Shares Out | 12.65M | 12.84M | 12.80M | 12.85M | 12.91M | 13.05M | 13.04M | 13.02M | 12.93M | 6.49M | 4.13M | 4.12M | 4.12M | 4.12M | 4.12M | 4.12M | 3.71M | 3.46M | 3.08M | 2.90M | 2.40M | 2.24M | 1.37M | 776.10K | 153.54K | 62.58K |
| Weighted Avg Shares Out (Dil) | 12.70M | 12.88M | 12.83M | 12.86M | 12.91M | 13.05M | 13.04M | 13.02M | 12.99M | 6.49M | 4.14M | 4.12M | 4.12M | 4.12M | 4.12M | 4.12M | 3.71M | 3.46M | 3.08M | 2.90M | 2.40M | 2.24M | 1.37M | 776.10K | 153.54K | 62.58K |
SWKH or MCO: Which Is the Better Value Stock Right Now?
SWKH vs. MCO: Which Stock Is the Better Value Option?
5 Affordable Breakout Stocks for Stunning Returns
BBW, LCUT, SWKH, VGR, and JMP passed the screen for Breakout Stocks for today.
Enteris BioPharma Receives 2021 Best of Boonton Award
BOONTON, N.J., Aug. 23, 2021 /PRNewswire/ -- Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation (Nasdaq: SWKH), announced that it has received the 2021 Best...
SWK Holdings Corporation (SWKH) CEO Winston Black on Q2 2021 Results - Earnings Call Transcript
SWK Holdings Corporation (SWKH) CEO Winston Black on Q2 2021 Results - Earnings Call Transcript
SWK Holdings Provides Portfolio Update Highlighting Recent Achievements
DALLAS, July 19, 2021 /PRNewswire/ -- SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the "Company"), a life science focused specialty finance company catering to small- and mid-sized commercial-stage companies, today provided an update on the achievements of its portfolio and partner...
SWK Holdings Corporation Resumes Share Repurchase Program
DALLAS, June 23, 2021 /PRNewswire/ -- SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the "Company"), a life science focused specialty finance company catering to small- and mid-sized commercial-stage companies, today announced that its Board of Directors has authorized the Company...
Enteris BioPharma to Host Webinar on High Potency Active Pharmaceutical Ingredients in Oral Drug Development
BOONTON, N.J., June 15, 2021 /PRNewswire/ -- Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation (Nasdaq: SWKH), announced that the company will host a...
Enteris BioPharma to Participate in BIO Digital 2021
BOONTON, N.J., June 7, 2021 /PRNewswire/ -- Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation (Nasdaq: SWKH), today announced that the company is participating...
SWK Holdings Corporation Announces Financial Results for First Quarter 2021
DALLAS, May 17, 2021 /PRNewswire/ -- Corporate Updates YTD SWK has closed two financings totaling up to $14.0 million Enteris BioPharma subsidiary announced completion of manufacturing facility expansion and launch of CDMO business SWK to form a strategic review committee...
Top Ranked Value Stocks to Buy for May 4th
Top Ranked Value Stocks to Buy for May 4th
Source: https://incomestatements.info
Category: Stock Reports